| Autor: |
Pallai R; Oncoveda, Cancer Signaling and Cell Cycle Team, Medical Diagnostic Laboratories, LLC, Genesis Biotechnology Group, 1000 Waterview Drive, Hamilton, NJ, 08691, USA., Bhaskar A, Barnett-Bernodat N, Gallo-Ebert C, Pusey M, Nickels JT Jr, Rice LM |
| Jazyk: |
angličtina |
| Zdroj: |
Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine [Tumour Biol] 2015 Aug; Vol. 36 (8), pp. 6383-90. Date of Electronic Publication: 2015 Apr 02. |
| DOI: |
10.1007/s13277-015-3326-1 |
| Abstrakt: |
Using yeast two-hybrid analysis, we identified several novel protein interactions for the oncoprotein Cancerous Inhibitor of PP2A (CIP2A) and confirmed a subset of these interactions in human cancer cell lines. Analysis of the interaction in prostate carcinoma cells between CIP2A and leucine-rich repeat-containing protein 59 (LRRC59) suggests that CIP2A is translocated into the nucleus at G2/M through its association with LRRC59. Recent work by others has demonstrated that nuclear CIP2A disrupts mitotic checkpoints, which promotes deregulation of the cell cycle and increases cancerous phenotypes. Thus, we provide a novel therapeutic mechanism for inhibiting CIP2A function in cancerous cells via targeting the CIP2A-LRRC59 interaction. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
Full text from SpringerLink